PRINCETON, N.J., June 21, 2024--Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with...
PRINCETON, N.J., June 21, 2024--European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
PRINCETON, N.J., June 20, 2024--Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024